Salarius Pharmaceuticals Inc

Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company. The firm focuses on the development of Salarius’ clinical pipeline, which targets rare, orphan cancers and cancers with a high unmet need. The company was founded in 2014 and is headquartered in Houston, TX.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. Its pipeline includes SP-3164, a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. The company was founded in February 2014 and is headquartered in Houston, TX.

Seclidemstat safety profile affirmed; Recommended Phase 2 dose established

Salarius Completes Dose-Escalation Stage of Phase 1/2 Clinical Trial in Relapsed and Refractory Ewing Sarcoma Patients, Initiates Expansion Stage in Ewing and Ewing-Related Sarcoma Patients

HOUSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that it will participate in the BIO CEO & Investor Digital Conference taking place Tuesday, February 16, 2021 to Thursday, February 18, 2021.

Salarius Pharmaceuticals to Present at BIO CEO & Investor Digital Conference

HOUSTON, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that it has received a letter from the Nasdaq Listing Qualifications staff notifying the Company that it has regained compliance with Nasdaq's Listing Rule 5550(a)(2) pertaining to the minimum bid price requirement for continued listing on the Nasdaq Capital Market.

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

HOUSTON, Jan. 15, 2021 (GLOBE NEWSWIRE) -- Salarius Pharm aceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that Daniela Y. Santiesteban, Ph.D., Director of Research and Business Development at Salarius Pharmaceuticals, has been invited to participate in a panel discussion during Noble Capital Markets' 17th Annual Small & Microcap Investor Conference (NobleCon17). The conference is taking place January 19-21, 2021 over a virtual platform.

Salarius Pharmaceuticals Announces Dr. Daniela Santiesteban to Participate in Panel Discussion on Targeted Cancer Therapies During Virtual NobleCon17 Investor Conference

HOUSTON, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today announced the receipt of a $0.9 million payment as the second installment of $1.7 million in scheduled payments to Salarius under its contract with the Cancer Prevention and Research Institute of Texas (CPRIT). The payments, which include the previously announced receipt of an $0.8 million disbursement announced on December 10, 2020, are part of an original non-dilutive grant awarded in 2016 to support Salarius' operations and development of its lead drug candidate, seclidemstat, for the treatment of Ewing sarcoma and other cancers. Seclidemstat is a reversible LSD1 inhibitor being studied in two clinical trials — one trial in relapsed/refractory Ewing sarcoma, a rare and deadly pediatric bone and soft tissue cancer, and a second trial in advanced solid tumors (AST). Up to $4.8 million in funding remains available to Salarius under the original 2016 CPRIT Award.

Salarius Pharmaceuticals Receives Second Installment of $1.7 Million in Payments from the Cancer Prevention and Research Institute of Texas

HOUSTON, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that the company is participating in Biotech Showcase Digital and BIO @ JPM. Both events will be held virtually and are scheduled alongside the J.P. Morgan 39th Annual Healthcare Conference 2021.

Salarius Pharmaceuticals to Participate in Biotech Showcase Digital and BIO @ JPM During "J.P. Morgan Week 2021"

HOUSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today announced that it has entered into agreements with several institutional and accredited investors (the “Exercising Holders”) to exercise certain outstanding warrants to purchase an aggregate of up to 3,964,065 shares of common stock raising gross proceeds of approximately $3.5 million. These warrants were previously issued in Salarius' public offering which closed in February 2020.

Salarius Announces Exercise Of Warrants For $3.5 Million Of Gross Proceeds To Be Used For Ongoing Development Of Seclidemstat

HOUSTON, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today announced the receipt of a $0.8 million payment as part of an expected $1.7 million in payments under its contract with the Cancer Prevention and Research Institute of Texas (CPRIT). The payments are part of an original non-dilutive grant of up to $18.7 million awarded in 2016 to support Salarius' operations and development of its lead drug candidate, seclidemstat, for the treatment of Ewing sarcoma and other cancers. Seclidemstat is a reversible LSD1 inhibitor being studied in two clinical trials — one trial in relapsed/refractory Ewing sarcoma, a rare and deadly pediatric bone cancer, and a second trial in advanced solid tumors (AST).

Salarius Pharmaceuticals Receives First Installment of $1.7 Million in Payments from the Cancer Prevention and Research Institute of Texas

HOUSTON, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors and other cancers, today announced its chief executive officer, David Arthur, will participate in A.G.P.'s Virtual Healthcare Symposium on Thursday, November 19, 2020.

Salarius Pharmaceuticals to Participate in A.G.P.'s Virtual Healthcare Symposium

Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q3 2020 Results - Earnings Call Transcript

Conference Call and Live Audio Webcast Scheduled for Today, November 11, 2020, at 4:30 p.m. ET Conference Call and Live Audio Webcast Scheduled for Today, November 11, 2020, at 4:30 p.m. ET

Salarius Pharmaceuticals Reports Business Highlights and Third Quarter 2020 Financial Results

Conference Call and Live Audio Webcast Scheduled for Wednesday, November 11, at 4:30 p.m. ET Conference Call and Live Audio Webcast Scheduled for Wednesday, November 11, at 4:30 p.m. ET

Salarius Pharmaceuticals to Report Third Quarter 2020 Financial Results

HOUSTON, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, LLC, a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, announced today that its Chief Executive Officer, David Arthur, will present at the BIO Investor Forum Digital conference taking place Tuesday, October 13, 2020 to Thursday, October 15, 2020. The presentation will be available on demand during the virtual event for all registered attendees.

Salarius Pharmaceuticals to Present at BIO Investor Forum Digital

Presentations Will Highlight Corporate and Clinical Progress Presentations Will Highlight Corporate and Clinical Progress

Salarius Pharmaceuticals to Present at Upcoming Investor Conferences

Webcast presentation scheduled for Tuesday, September 1, 2020 Webcast presentation scheduled for Tuesday, September 1, 2020

Salarius Pharmaceuticals to Present During Virtual LD 500 Conference

Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q2 2020 Results - Earnings Call Transcript

Company Closes $6.2M Public Offering and Expands Clinical Program to Include Ewing-Related Sarcomas

Salarius Pharmaceuticals Reports Business Highlights and Second Quarter 2020 Financial Results

Conference Call and Live Audio Webcast Scheduled for Wednesday, August 12, at 4:30 p.m. ET Conference Call and Live Audio Webcast Scheduled for Wednesday, August 12, at 4:30 p.m. ET

Salarius Pharmaceuticals to Report Second Quarter 2020 Financial Results

New Patent Protects Composition of Matter and Methods of Use Through At Least August 2032 New Patent Protects Composition of Matter and Methods of Use Through At Least August 2032

Salarius Announces Issuance of New Patent for Seclidemstat by European Patent Office

HOUSTON, July  30, 2020  (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced the pricing of an underwritten public offering of 4,461,209 shares of its common stock at a price to the public of $1.20 per share. All of the shares are being sold by Salarius. The gross proceeds to Salarius from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $5.3 million. The closing of the offering is expected to take place on or about August 3, 2020, subject to the satisfaction or waiver of customary closing conditions. In addition, Salarius has granted the underwriter a 45-day option to purchase up to 669,181 additional shares of common stock at the public offering price per share, less underwriting discounts and commissions.

Salarius Announces Pricing of $5.3 Million Underwritten Public Offering

Pre-Clinical Data and Early Clinical Observations Support Company’s Decision to Research Seclidemstat as a Potential Treatment in Ewing-Related Sarcomas Pre-Clinical Data and Early Clinical Observations Support Company’s Decision to Research Seclidemstat as a Potential Treatment in Ewing-Related Sarcomas

Salarius Pharmaceuticals to Expand Clinical Program to Target Additional Sarcomas in Ewing Sarcoma Phase 1/2 Clinical Trial

Biogen

Coherus BioSciences

Gen Digital Inc

Lexicon Pharmaceuticals

A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company’s future growth prospects.

5 Value Stocks In The Healthcare Sector

Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q1 2020 Results - Earnings Call Transcript

Seclidemstat Advances Dose Escalation in Phase 1/2 Ewing Sarcoma Clinical Trial; On Track to Report Early Data in 2020

Salarius Pharmaceuticals Reports First Quarter 2020 Financial Results

Board of Directors Seeks the Election of Jonathan Lieber, Industry Veteran with Deep Financial and Wall Street Expertise, as a New, Independent Director Board of Directors Seeks the Election of Jonathan Lieber, Industry Veteran with Deep Financial and Wall Street Expertise, as a New, Independent Director

News for Salarius Pharmaceuticals Inc Stock (SLRX)